top of page
Akamis Bio Header Image

Publications

Phase 1 Study of Intravenous Administration of the Chimeric Adenovirus Enadenotucirev in Patients Undergoing Primary Tumor Resection

Garcia-Carbonero R, Salazar R, Duran I, Osman-Garcia I, Paz-Ares L, Bozada JM, Boni V, Blanc C, Seymour L, Beadle J, Alvis S, Champion B, Calvo E, Fisher K.  
Journal for ImmunoTherapy of Cancer2017 5:71

Click Here for Full Text

Clinical Trial Design Poster NG-350A (FORTITUDE) ASCO 2019

A multicenter, open-label, first in human study of a vector expressing and agonistic anti-CD40 antibody (NG-350A) in patients with epithelial tumors.

Click to Access Poster

Pre Clinical Studies Poster for NG-641 (SITC 2017)

NG-641: A T-SIGn vector targeting cancer-associated fibroblasts in the stromal microenvironment of human carcinomas.

Click to Access Poster

Directed evolution generates a novel oncolytic virus for the treatment of colon cancer

Kuhn I, Harden P, Bauzon M, Chartier C, Nye J, Thorne S, Reid T, Ni S, Lieber A, Fisher K, Seymour L, Rubanyi GM, Harkins RN, Hermiston TW. PLoS ONE 2008; 3 (6):e2409.

Click Here for Full Text

Expression of human CD46 and transcomplementation by murine adenovirus 1 fails to allow productive infection by a group B oncolytic adenovirus in murine cancer cells

Janet Lei, Egon J. Jacobus, William K. Taverner, Kerry D. Fisher, Silvio Hemmi, Katy West, Lorna Slater, Fred Lilley, Alice Brown, Brian Champion, Margaret R. Duffy and Len W. Seymour
Journal for ImmunoTherapy of Cancer (2018) 6:55

Click Here for Full Text

External Beam Radiation Therapy and Enadenotucirev: Inhibition of the DDR and Mechanisms of Radiation-Mediated Virus Increase

Tzveta D. Pokrovska, Egon J. Jacobus, Rathi Puliyadi, Remko Prevo, Sally Frost, Arthur Dyer, Richard Baugh, Gonzalo Rodriguez-Berriguete, Kerry Fisher, Giovanna Granata, Katharine Herbert, William K. Taverner, Brian R. Champion, Geo S. Higgins, Len W. Seymour,* and Janet Lei-Rossmann
Cancers 2020, 12, 798

Click Here for Full Text

Calcium Influx Caused by ER Stress Inducers Enhances Oncolytic Adenovirus Enadenotucirev Replication and Killing through PKCα Activation

William K. Taverner, Egon J. Jacobus, John Christianson, Brian Champion, Adrienne W. Paton, James C. Paton, Weiheng Su, Ryan Cawood, Len W. Seymour, and Janet Lei-Rossmann
Molecular Therapy: Oncolytics Vol. 15 December 2019

Click Here for Full Text

Oncolytic viruses: finally delivering.

Seymour LW, Fisher KD. British Journal of Cancer. 2016;114:357–61

Click Here for Full Text

Oncolytic Group B Adenovirus Enadenotucirev Mediates Non-apoptotic Cell Death with Membrane Disruption and Release of Inflammatory Mediators

Dyer A, Ying D, Calderon H, Illingworth S, Kueberuwa G, Tedcastle A, et al. Mol Ther Oncolytics. 2017;4:18-30.

Click Here for Full Text

Group B adenovirus enadenotucirev infects polarised colorectal cancer cells efficiently from the basolateral surface expected to be encountered during intravenous delivery to treat disseminated cancer

Chiaa SL, Leia J, Fergusonc D, Dyera A, Fisher K, Seymour L.  Virology 505 (2017) 162–171

Click Here for Full Text
Cell Therapy Paper Anchor
bottom of page